Effect of leech therapy in increased d-dimer laboratory values.

A clinical trial to evaluate the effect of jalaukavacharana in increased d-dimer laboratory values

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048609

Enrollment

Registered

2022-12-30

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D689- Coagulation defect, unspecified Health Condition 2: D65- Disseminated intravascular coagulation [defibrination syndrome] Health Condition 3: I829- Embolism and thrombosis of unspecified vein Health Condition 4: I998- Other disorder of circulatory system Health Condition 5: D686- Other thrombophilia Health Condition 6: I838- Varicose veins of lower extremities with other complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients those have increased D-dimer values in Deep vein thrombosis (DVT), Disseminated intravascular coagulation, Hepatomegaly and Post convalescence SARS Covid-19 patients(after 3 months)will be selected for study. 2.Participants of any gender in between 16 to 70 ages. 3.Participants who are willing for the study.

Exclusion criteria

Exclusion criteria: 1.Absolute Hemophiliac and other bleeding disorders. 2.Anticoagulant medicines like Warfarin, Heparin, etc. 3.Severe Anemia. 4.Erosive Gastritis and potential gastrointestinal bleeding. 5.During Chemotherapy. 6.Individuals with HIV infection. 7.Severe Allergic Diathesis (allergy foreign proteins). 8.Hypotension 9.Active Tuberculosis. 10.Pregnancy 11.Mental disorders during acute episodes. 12.Severe ill and bed patient. 13.Acute DVT 14.Pulmonary Embolism 15.Malignancy 16.Participants who are known cases of renal failure, neurological, Diagnosed with CA, and also with psychological disturbances. 17.Uncontrolled systemic conditions like Diabetes mellitus. 18.Cirrhosis of the Liver 19.Coagulopathies.

Design outcomes

Primary

Measure	Time frame
1.Changes in the D-dimer values after Jalaukavacharana. 2.Complete reduction of pain. 3.Reduction of blood clot and increases blood circulation in body.Timepoint: 34 days	—

Secondary

Measure	Time frame
1.Any general improvement of in other aspects of health. 2. Reduction of thromboembolic conditions.Timepoint: 2 month	—

Countries

India

Contacts

Public ContactDr T Udayakiran

Sri Jayendra Saraswathi Ayurveda college and Hospital

dr_tenneti@yahoo.co.in9849666054

Outcome results